Italy-based Stevanato, a provider of drug containment, drug delivery and diagnostic solutions, has commenced construction of a new production facility in Fishers, Indiana. The plant is expected to be operational in 2023 and will allow the company to better serve pharmaceutical, biotechnology and life sciences companies in North America.

The company plans to invest $145m to establish the plant, which it will use as a centre for after-sales support as well as to offer technical support and maintenance services. It will cover 34,370m2 and will be staffed with more than 230 local employees by the end of 2025.

Franco Moro, Stevanato Group CEO, explained in a company press release: “We are thrilled to begin construction on our new US hub, and expand our presence in one of the fastest-growing markets, where we see increasing demand. We believe this will allow us to further enhance our services to our valued North America customers and it underscores our desire to ensure supply chain security, just-in-time delivery and reliable sourcing in terms of surge capacity.”

The new Fishers plant will complement the firm’s existing US operations, which include a technology centre of excellence in Boston and a device manufacturing facility in California.